[ad_1]
AstraZeneca vaccine ▶ Click here to enlarge the view
An expert monitoring adverse reactions to thrombus in Korea said that “the European judgment that the benefit of vaccination is much greater has not changed” regarding the limited use of vaccines for infection with the novel AstraZeneca (AZ) coronavirus ( Corona 19) in some countries. Emphasized.
Professor Na Sang-hoon from the Department of Cardiology at Seoul National University School of Medicine said: “Some countries, including Germany and Canada, have announced that they will not use the AstraZeneca vaccine in a certain age group, but the Agency European Medicines (EMA) said on March 18, 31, said: “We will continue to observe thrombosis at specific sites because the vaccine has a much greater benefit.”
“The benefits of vaccination are also much greater in Germany and Canada, but there are concerns about certain age groups, so we will temporarily stop AstraZeneca as long as we do not miss the general vaccination schedule,” he said.
He added: “In the case of cerebral sinus thrombosis (CVST), it is a rare disease that occurs in 1 to 2 people per 100,000 inhabitants in Europe, and it is a problem when the number of patients 2 to 3 times more after AstraZeneca Vaccination occurs. “In the case of generalized thrombosis, which occurs in more than 150 people per person, the number of patients has been reduced to a third,” he explained.
“Taken together, AstraZeneca has the effect of significantly reducing the incidence of thrombosis itself,” he said. “In Korea, the incidence of thrombosis is less than a fifth of that in Europe, so the incidence of CVST will be much lower.”
Professor Na said that the Corona 19 first responder, who was diagnosed with CVST after vaccination with AstraZeneca, was discharged after a week of hospital treatment.
He said: “In general, thrombosis is treated with blood thinners if there are no additional complications, and he is discharged from the hospital after an average of a week.”
He explained that genetic history and autoantibody disease tests were performed to determine the cause of the thrombosis, but the initial testing did not find any details.
[연합뉴스]
Copyright ⓒ Yonhap News. Unauthorized reproduction and redistribution prohibited
